|
|
|
May 3, 2012 | Rare diseases affect fewer than 200,000 individuals, but the small consumer pool hasn't negated research for these diseases, rather good drugs for rare diseases can make pharma companies quite a lot of money. Finding a balance between the profits and patients, though, is always a bit tricky, and Forbes contributor John LaMattina believes this could only become more troublesome if regulatory action controls drug costs. Forbes
|
|
|